Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis

作者：Shi, Youwu; Zhou, Shengyu; He, Xiaohui; Han, Xiaohong; Wu, Shikai; Pan, Feng; Liu, Peng; Liu, Yinyu; Lei, Yingheng; Zhang, Hongzhi; Yang, Jianliang; Qin, Yan; Zhang, Changgong; Yang, Sheng; Zhao, Liya; Luo, Kehuan; Wu, Guanqing; Sun, Yan; Shi, Yuankai

来源：Chinese Journal of Cancer Research, 2015, 27(1): 66-73.

DOI：10.3978/j.issn.1000-9604.2015.02.04

• Lymphoblastic lymphoma (LL)
• high-dose therapy (HDT)
• hematopoietic stem cell transplantation (HSCT)
• autologous
• allogeneic

Objective: The study evaluated the effectiveness of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of lymphoblastic lymphoma (LL).
Methods: We retrospectively analyzed the data from 41 patients with chemotherapy-sensitive LL who underwent hematopoietic stem cell transplantation (HSCT) from December 1989 to December 2009 in a single institution.
Results: HSCT was conducted as first-line consolidation therapy and salvage therapy in 36 and 5 patients, respectively. The median follow-up was 97.1 months (range, 24.6-173.1 months). The 5-year overall survival (OS) and event-free survival (EFS) rate were 64% and 47% for the initially treated patients, respectively, and were both 20% for the relapsed ones. Bone marrow (BM) involvement and chemotherapy cycles prior to transplantation were identified as significant prognostic factors for EFS in multivariate analysis.
Conclusions: These results confirm that AHSCT is a reasonable option for chemotherapy-sensitive LL patients in first complete remission (CR1).

• 出版日期2015-2
• 单位中国医学科学院肿瘤医院; 中国医学科学院北京协和医院